APA
Click to copy
Adesanya, E. I., Matthewman, J., Schonmann, Y., Hayes, J. F., Henderson, A. D., Mathur, R., … Mansfield, K. (2022). Factors associated with depression, anxiety, and severe mental illness among adults with atopic eczema or psoriasis: a systematic review and meta-analysis. British Journal of Dermatology.
Chicago/Turabian
Click to copy
Adesanya, Elizabeth I, Julian Matthewman, Yochai Schonmann, Joseph F Hayes, Alasdair D Henderson, R. Mathur, Amy R Mulick, Catherine H Smith, Sinéad M Langan, and K. Mansfield. “Factors Associated with Depression, Anxiety, and Severe Mental Illness among Adults with Atopic Eczema or Psoriasis: a Systematic Review and Meta-Analysis.” British Journal of Dermatology (2022).
MLA
Click to copy
Adesanya, Elizabeth I., et al. “Factors Associated with Depression, Anxiety, and Severe Mental Illness among Adults with Atopic Eczema or Psoriasis: a Systematic Review and Meta-Analysis.” British Journal of Dermatology, 2022.
BibTeX Click to copy
@article{elizabeth2022a,
title = {Factors associated with depression, anxiety, and severe mental illness among adults with atopic eczema or psoriasis: a systematic review and meta-analysis},
year = {2022},
journal = {British Journal of Dermatology},
author = {Adesanya, Elizabeth I and Matthewman, Julian and Schonmann, Yochai and Hayes, Joseph F and Henderson, Alasdair D and Mathur, R. and Mulick, Amy R and Smith, Catherine H and Langan, Sinéad M and Mansfield, K.}
}
Evidence suggests an association between atopic eczema (AE) or psoriasis and mental illness. However, factors associated with mental illness are unclear.
To synthesise and evaluate all available evidence on factors associated with depression, anxiety, and severe mental illness (SMI) among adults with AE or psoriasis.
We searched electronic databases, grey literature databases, and clinical trial registries from inception to February 2022 for studies in adults with AE or psoriasis. Eligible studies were randomised controlled trials (RCTs), cohort, cross-sectional or case-control studies where effect estimates of factors associated with depression, anxiety, or SMI were reported. We did not apply language or geographical restrictions. We assessed risk of bias using the Quality in Prognosis Studies tool. We synthesised results narratively, and if at least two studies were sufficiently homogenous, we pooled effect estimates in a random-effects meta-analysis.
We included 21 studies (11 observational, 10 RCT). No observational studies in AE fulfilled our eligibility criteria. Observational studies in people with psoriasis mostly investigated factors associated with depression or anxiety – one cross-sectional study investigated factors associated with schizophrenia. Pooled effect estimates suggest being female, and psoriatic arthritis, were associated with depression (female sex:OR = 1.62,95%CI = 1.09-2.40,95%PI = 0.62-4.23, I2 = 24.90%, Tau2 = 0.05; psoriatic arthritis:OR = 2.26,95%CI = 1.56-3.25,95%PI = 0.21-24.23, I2 = 0.00%, Tau2 = 0.00) and anxiety (female sex:OR = 2.59,95%CI = 1.32-5.07,95%PI = 0.00-3956.27, I2 = 61.90%, Tau2 = 0.22; psoriatic arthritis:OR = 1.98,95%CI = 1.33-2.94, I2 = 0.00%, Tau2 = 0.00). Moderate/severe psoriasis was associated with anxiety (OR = 1.14,95%CI = 1.05-1.25, I2 = 0.00%, Tau2 = 0.00), but not depression. Evidence from RCTs suggested adults with AE or psoriasis given placebo had higher depression and anxiety scores compared to comparators given targeted treatment (e.g., biologic agents).
Our review highlights limited existing research on factors associated with depression, anxiety, and SMI in adults with AE or psoriasis. Observational evidence on factors associated with depression or anxiety in people with psoriasis was conflicting or from single studies, but some identified factors were consistent with those in the general population. Evidence on factors associated with SMIs in people with AE or psoriasis was particularly limited. Evidence from RCTs suggested AE and psoriasis treated with placebo was associated with higher depression and anxiety scores compared to skin disease treated with targeted therapy, however, follow-up was limited, therefore long-term effects on mental health are unclear.